Examine the Opportunities for Long Term Growth in Follow On Biologics

Share Article

SMi’s 4th annual Biosimilars and Biobetters conference will take place on the 24th & 25th September London, promises to present attendees with the perfect forum to discuss the rising development cost of biosimilars and successful marketing and pricing strategies, with a focus on case studies from those who are both developing and distributing follow on biologics.

News Image
Complicated processes made clear!" - Abbott

"Great speakers with interesting contributions" - Genentech

This event will act as a unique platform to hear from and discuss with key experts in the field on key issues such as understanding the latest regulatory developments, developing biosimilar monoclonal antibodies and trends of biosimilars in emerging markets. Attending will enable you to:

Consider developments of biosimilar monoclonal antibodies and their global commercial opportunity
Discover biosimilars for recombinant human insulin and insulin glargine
Discuss both biosimilars and biobetters; which strategy provides a better ROI?
Identify patient risk factors and prepare techniques for risk minimisation
Evaluate current and future developments in intellectual property and patent protection
Learn about new variations in global regulatory strategies for biosimilar development

For more information visit http://www.smi-online.co.uk/goto/biosimilars-biobetters76.asp alternatively contact Fateja Begum on +44 0 207 827 6184 or email on fbegum@smi-online.co.uk

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sonal Patel
SMi Group Ltd
0207 827 6106
Email >
Follow us on
Visit website